# US 2020/0400558 A1 · Fetal lung maturity test

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400558 A1
- Document ID: US20200400558A1
- Status: Published application
- Kind: A1
- Application number: 16/754,009
- Filed: 2018-10-05
- Published: 2020-12-24
- Earliest claimed: 2017-10-06
- Assignees: Sime Diagnostics Ltd.
- Applicants: Sime Diagnostics Ltd.
- Inventors: Peter SCHOUSBOE; Henrik VERDER
- Web page: https://patentgrep.com/patent/US20200400558A1

## CPC

- G01N 21/3577: for analysing liquids, e.g. polluted water
- G01N 1/4077: {by other techniques involving separation of suspended solids}
- G01N 33/487: of liquid biological material
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A61B 5/08: Measuring devices for evaluating the respiratory organs
- A61B 5/4362: {Assessing foetal parameters}
- A61B 2503/045: Newborns, e.g. premature baby monitoring
- G01N 2001/4083: {sedimentation}
- G01N 2021/3595: {using FTIR}
- G01N 2405/04: Phospholipids, i.e. phosphoglycerides
- G01N 2405/08: Sphingolipids
- G01N 2800/12: Pulmonary diseases
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The present invention relates to methods for diagnosing Respiratory Distress Syndrome of newborn.

## Claims

### Claim 1

A method for diagnosing Respiratory Distress Syndrome (RDS) in a subject, the method comprising the steps of:
i) providing a sample from said subject, wherein the sample is an amniotic fluid sample, a blood sample, an oropharyngeal secretion sample or a gastric aspirate sample, preferably the sample is a gastric aspirate sample or an oropharyngeal secretion;
ii) homogenising and diluting said sample in a first volume of a first solution, thereby obtaining a homogenous sample;
iii) centrifuging the sample of step ii) to obtain a pellet comprising lamellar bodies, and a supernatant;
iv) discarding the supernatant and resuspending the pellet in a second volume of a second solution, thereby obtaining a sample for analysis;
v) determining the amount of a first compound selected from lecithin and saturated lecithin and optionally the amount of sphingomyelin in the sample for analysis, using analysis means;
vi) obtaining a concentration of the first compound and/or a ratio between the first compound and sphingomyelin;
vii) correlating the concentration of vi) with a control value, wherein a concentration equal to or lower than the control value is indicative of the subject having Respiratory Distress Syndrome (RDS); and/or correlating the ratio of vi) with a control ratio, wherein a ratio equal to or lower than the control ratio is indicative of the subject having Respiratory Distress Syndrome (RDS).

### Claim 2

The method according to any one of the preceding claims, wherein the sample has a volume between 10 and 1000 μL, such as between 10 and 750 μL, such as between 20 and 500 μL, such as between 30 and 250 μL, such as between 40 and 125 μL, such as between 50 and 100 μL, such as between 60 and 90 μL, such as between 70 and 80 μL, such as 50 μL, 75 μL or 100 μL.

### Claim 3

The method according to any one of the preceding claims, wherein the first solution is a hypotonic solution such as water or deionised water.

### Claim 4

The method according to any one of the preceding claims, wherein the ratio of the volume of the sample of step i) to the volume of the first solution used in step ii) is between 1:1 and 1:10, such as 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10, preferably 1:4 or 1:6.

### Claim 5

The method according to any one of the preceding claims, wherein the centrifugation of step iii) is performed at a force between 500 and 10000 g, such as 4000 g, for a duration of 1 min to 10 min, such as 2 min to 9 min, such as 3 min to 8 min, such as 4 min to 7 min, such as 5 min to 6 min, such as 4 min, 5 min or 6 min.

### Claim 6

The method according to any one of the preceding claims, wherein the second solution is a hypotonic solution such as water or deionised water, or saline solution.

### Claim 7

The method according to any one of the preceding claims, wherein the analysis means is selected an infrared spectrometer, such as a Fourier transformed infrared (FTIR) spectrometer.

### Claim 8

The method according to any one of the preceding claims, further comprising determining the amount of a further compound such as phosphatidylglycerol.

### Claim 9

The method according to any one of the preceding claims, wherein the time-to-result of the method is between 5 and 60 minutes, such as between 8 and 30 minutes, such as 15 minutes.

### Claim 10

The method according to any one of the preceding claims, wherein the control ratio is between 1.0 and 3.0±0.5, such as between 1.5 and 2.9±0.5, such as between 2.0 and 2.8±0.5, such as between 2.2 and 2.7±0.5, such as between 2.4 and 2.6±0.5, such as 2.5±0.5 or 2.0±0.5, or between 2.0 and 5.0±0.5, such as between 2.2 and 4.5±0.5, such as between 2.4 and 4.0±0.5, such as between 2.6 and 3.5±0.5, such as between 2.8 and 3.2±0.5, such as 3±0.5.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method of treatment of Respiratory Distress Syndrome (RDS) in a newborn individual, comprising the steps of:
i) providing a sample from said newborn individual, wherein the sample is an amniotic fluid sample, a blood sample, an oropharyngeal secretion sample or a gastric aspirate sample;
ii) diluting and homogenising said sample in a first volume of a first solution, thereby obtaining a homogenous sample;
iii) centrifuging the homogenous sample to obtain a pellet comprising lamellar bodies and a supernatant;
iv) discarding the supernatant and resuspending the pellet in a second volume of a second solution, thereby obtaining a sample for analysis;
v) determining the amount of a first compound selected from lecithin and saturated lecithin and optionally the amount of sphingomyelin in the sample for analysis, using analysis means;
vi) obtaining a concentration of the first compound and optionally a ratio between the first compound and sphingomyelin;
vii) correlating the concentration of vi) with a control value, wherein a concentration equal to or lower than the control value is indicative of the subject having Respiratory Distress Syndrome (RDS); and/or correlating the ratio of vi) with a control ratio, wherein a ratio equal to or lower than the control ratio is indicative of the subject having Respiratory Distress Syndrome (RDS);
viii) if the concentration of vi) is equal to or less than the control value and/or if the ratio of vi) is equal to or less than the control ratio, administering a therapeutically effective amount of surfactant to the newborn individual,
optionally wherein steps i) to vii) are performed as defined in any one of claims 1 to 10.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the control ratio is between 1.0 and 3.0±0.5, such as between 1.5 and 2.9±0.5, such as between 2.0 and 2.8±0.5, such as between 2.2 and 2.7±0.5, such as between 2.4 and 2.6±0.5, such as 2.5±0.5 or 2.0±0.5, or between 2.0 and 5.0±0.5, such as between 2.2 and 4.5±0.5, such as between 2.4 and 4.0±0.5, such as between 2.6 and 3.5±0.5, such as between 2.8 and 3.2±0.5, such as 3±0.5.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A computer implemented method for diagnosing RDS based on spectral data acquired from a sample obtained from a subject, wherein the sample is an amniotic fluid sample, a blood sample, an oropharyngeal secretion sample or a gastric aspirate sample, the method comprising the steps of:
i) determining the activity and/or concentration of a first compound selected from lecithin and saturated lecithin and optionally of sphingomyelin in said sample by acquiring spectral data for the sample,
ii) optionally calculating a ratio between the activities and/or concentrations of sphingomyelin and of the first compound,
iii) correlating said concentration with a control value and optionally correlating said ratio with a control ratio, wherein a concentration equal to or lower than the control value and/or a ratio equal to or lower than the control ratio is indicative of RDS of the subject
wherein the method optionally further comprises the features of any of claims 1 to 10.

### Claim 14 (depends on 13)

A computer program product having a computer readable medium, said computer program product suitable for diagnosing RDS of a subject based on spectral data acquired from a sample obtained from said subject, wherein the sample is an amniotic fluid sample, a blood sample, an oropharyngeal secretion sample or a gastric aspirate sample, said computer program product comprising means for carrying out all the steps of the method as defined in claim 13.

### Claim 15

A system for diagnosing RDS based on a sample obtained from said subject, wherein the sample is an amniotic fluid sample, a blood sample, an oropharyngeal secretion sample or a gastric aspirate sample, comprising
a spectroscope for measuring spectral data from said sample,
processing means configured for
a) determining the activity and/or concentration of a first compound selected from lecithin and saturated lecithin and/or of sphingomyelin in said sample by analysing said spectral data,
b) calculating a concentration of the first compound and optionally a ratio between the activities and/or concentrations of the first compound and sphingomyelin, and
c) correlating said concentration with a control concentration and optionally correlating said ratio with a control ratio, and
d) indicating whether the concentration is equal to or lower than the control value and optionally indicating if the ratio is equal to or lower than the control ratio, wherein a predefined difference is indicative of Respiratory Distress Syndrome (RDS) of the subject.
